Advances in the medical management of endometriosis.
Panay
N
N
Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust, London, UK. nickpanay@msn.com
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D003276:Contraceptives, Oral / Q000627:therapeutic use; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D016912:Levonorgestrel / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013256:Steroids / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D047072:Aromatase Inhibitors; D003276:Contraceptives, Oral; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007155:Immunologic Factors; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013256:Steroids; D016912:Levonorgestrel